Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 20/20 | 0.55 |
| ▸ | PIK3R1 | P27986 | 18/20 | 0.55 |
| ▸ | PIK3CD | O00329 | 8/20 | 0.55 |
| ▸ | PIK3CB | P42338 | 7/20 | 0.55 |
| ▸ | PIK3CG | P48736 | 7/20 | 0.55 |
| ▸ | MTOR | P42345 | 6/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27009132 | 0.83 | PIK3CD (0.38) | PIK3CAPIK3R1PIK3CDPIK3CBPIK3CG | |
| SCHEMBL24378626 | 0.82 | PIK3CA (0.44) | PIK3CAPIK3R1PIK3CDPIK3CBPIK3CG | |
| SCHEMBL24378634 | 0.78 | HPGD (0.43) | PIK3CAPIK3R1PIK3CDPIK3CBPIK3CG | |
| SCHEMBL24378567 | 0.78 | MAPT (0.42) | — | |
| SCHEMBL21517903 | 0.78 | PIK3CD (0.58) | PIK3CAPIK3R1PIK3CDPIK3CBPIK3CG | |
| SCHEMBL29547027 | 0.78 | PIK3CD (0.43) | PIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL21517868 | 0.76 | PIK3CA (0.64) | PIK3CAPIK3R1PIK3CDPIK3CBPIK3CG | |
| SCHEMBL24378565 | 0.76 | MAPT (0.40) | PIK3CAPIK3R1 | |
| SCHEMBL24378555 | 0.75 | PIK3CA (0.46) | PIK3CAPIK3R1PIK3CDPIK3CBPIK3CG | |
| SCHEMBL13815704 | 0.72 | KMT2A (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018151-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | TME THERAPEUTICS LLC | 2024-01-18 | — | — | US | disclosed |
| US-20240018151-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | TME THERAPEUTICS LLC | 2024-01-18 | — | — | US | disclosed |
| EP-4229063-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | TME Therapeutics LLC (US) | 2023-08-23 | — | — | EP | disclosed |
| WO-2022086993-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | TME THERAPEUTICS LLC (US) | 2022-04-28 | — | — | WO | disclosed |
| WO-2022086993-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | TME THERAPEUTICS LLC (US) | 2022-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018151-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | PIKFYVE, PIK3CD, PIK3R5 | PIK3CA 11/4885PIK3R1 20/4885PIK3CD 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.